This will be a an open-label, 3-period fixed sequence study to be conducted at a single study centre.~The treatment starts with AZD4831 (Treatment Period 1), followed by Itraconazole administration for 3 days (Treatment Period 2) and finally a combination of AZD4831+Itraconazole administration (Treatment Period 3).~The study will comprise of:~A Screening Period of approximately 28 days.~Three Treatment Periods:~Treatment Period 1 (Day -1 through pre-dose Day 8): Single oral dose of AZD4831 only on Day 1,~Treatment Period 2 (Day 8 through pre-dose Day 11): Oral dose of Itraconazole only on Days 8 through 10,~Treatment Period 3 (Day 11 through Day 18, after the last PK sample is collected): AZD4831 and Itraconazole on Day 11 and oral dosing of Itraconazole only on Days 12 through 17.~A final Follow-up Visit after the last PK sample (Day 25 to Day 32).~Each subject will be involved in the study for approximately 9 weeks (including the 28 day Screening Period).
A study to demonstrate pharmacokinetics of AZD4831 when administered alone and in combination with Itraconazole.